Phase 1/2a Study to Evaluate the Safety, Activity, and Pharmacokinetics of Escalating Doses of GNS561 in Patients With Advanced Malignancies Including Hepatocellular Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs GNS 561 (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Liver cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Sponsors Genoscience
- 14 Jul 2019 Planned number of patients changed from 50 to 122.
- 02 May 2018 Status changed from not yet recruiting to recruiting.
- 24 Oct 2017 New trial record